ArticleNature2023
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.
Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06551909 (Radioimmunotherapy in Solid Tumors), which is not on this map. Cited by 200 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
200citing papers in PubMed, 4 pooled it
71.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Radioimmunotherapy in Solid Tumors (Aim 2- Stereotactic Neoadjuvant Radiotherapy for Glioblastoma)
Who cites it
200 citing papers in PubMed, 4 syntheses or guidelines pooled it, 229 citations in OpenAlex.
- Pooled it
- T cell immunity in glioma and potential implications for immunotherapy: A systematic review.Neuro-oncology · 2026Pooled it
- Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.Journal of virology · 2025Pooled it
- Scientometric analysis of glioblastoma and blood-brain barrier research (1995-2024): evolving trends and therapeutic challenges.Frontiers in oncology · 2025Pooled it
- Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.Nature medicine · 2026Trial
- Systemic Immune Correlates of Long-term Survival after Delta-24-RGD Based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: A single-arm, phase 1/2 study.Neuro-oncology · 2026Trial
- Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation.Oncoimmunology · 2026Article
- Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot.Human vaccines & immunotherapeutics · 2026Review
- Syncytium-forming HSV-1 in cancer gene therapy: From molecular mechanisms to clinical translation.Virulence · 2026Review
- In situ APMV-4 vaccination primes systemic response to subtherapeutic dosing of aCTLA-4 in colorectal carcinoma.Journal for immunotherapy of cancer · 2026Article
- Precision virotherapy for IDH-mutant astrocytoma.Molecular therapy. Oncology · 2026Article
- Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma.Oncogene · 2026Article
- Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.Nature reviews. Clinical oncology · 2026Review
- Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer.International journal of molecular sciences · 2026Review
- Optimization of CEST MRI Reporter Protein Design Using Cation-Pi Networks.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Identifying a Csmd3Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Diverse origin and nature of tumor-infiltrating lymphocytes: the infection hypothesis.Journal for immunotherapy of cancer · 2026Review
- Circadian-guided oncolytic virotherapy for glioblastoma.Journal of neurovirology · 2026Review
- Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.Experimental hematology & oncology · 2026Review
140 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
61 authors at 9 institutions in 2 countries.
Alexander L Ling *Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Isaac H Solomon *Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-3432-0902
Ana Montalvo Landivar *Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Hiroshi Nakashima *Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Jared K WoodsDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Andres SantosHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Nafisa MasudHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Geoffrey FellDepartment of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA.
Xiaokui MoCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-9797-2687
Ayse S YilmazCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
James GrantHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Abigail ZhangHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Joshua D BernstockHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-7814-3867
Erickson TorioHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-0958-704X
Hirotaka ItoHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Junfeng LiuHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Naoyuki ShonoHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Michal O NowickiHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Daniel TriggsHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Patrick HalloranHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Raziye PiranliogluHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-2450-3887
Himanshu SoniHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Brittany StopaHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Wenya Linda BiHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-4635-0247
Pierpaolo PeruzziHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Ethan ChenHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Seth W MalinowskiDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Michael C PrabhuDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Yu ZengDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Anne CarlisleCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Patrick Y WenCenter for Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eudocia Quant LeeCenter for Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lakshmi NayakCenter for Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ugonma ChukwuekeCenter for Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-0598-9535
L Nicolas Gonzalez CastroCenter for Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sydney D DumontDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Tracy BatchelorDepartment of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Kara KittelbergerClearPoint Neuro, Solana Beach, CA, USA.
Ekaterina TikhonovaBostonGene, Waltham, MA, USA.
Natalia MiheechevaBostonGene, Waltham, MA, USA.ORCID 0000-0002-6487-5514
Dmitry TabakovBostonGene, Waltham, MA, USA.ORCID 0000-0002-1509-2206
Nara ShinBostonGene, Waltham, MA, USA.ORCID 0000-0002-9910-4971
Alisa GorbachevaBostonGene, Waltham, MA, USA.
Artemy ShumskiyBostonGene, Waltham, MA, USA.
Felix FrenkelBostonGene, Waltham, MA, USA.ORCID 0000-0002-8958-7447
Estuardo Aguilar-CordovaCandel Therapeutics, Needham, MA, USA.
Laura K AguilarCandel Therapeutics, Needham, MA, USA.ORCID 0000-0002-3473-0330
David KriskyCandel Therapeutics, Needham, MA, USA.
James WechuckCandel Therapeutics, Needham, MA, USA.
Andrea ManzaneraCandel Therapeutics, Needham, MA, USA.
Chris MathenyCandel Therapeutics, Needham, MA, USA.ORCID 0000-0001-7860-2173
Paul P TakCandel Therapeutics, Needham, MA, USA.
Francesca BaroneCandel Therapeutics, Needham, MA, USA.
Daniel KovarskyDepartment of Molecular Cell Biology, Weizmann Institute of Medical Sciences, Tel Aviv, Israel.
Itay TiroshDepartment of Molecular Cell Biology, Weizmann Institute of Medical Sciences, Tel Aviv, Israel.ORCID 0000-0001-5477-2987
Mario L SuvàDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-9898-5351
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1829-302X
Keith LigonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-7733-600X
David A ReardonCenter for Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-6674-0157
E Antonio ChioccaHarvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA. eachiocca@bwh.harvard.edu.ORCID 0000-0001-5183-1670
Brigham and Women's Hospital · USCelldex Therapeutics (United States) · USAddgene · USCenter for Neuro-Oncology · USDana-Farber Cancer Institute · USBroad Institute · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USWeizmann Institute of Science · ILClearPoint Neuro (United States) · US
Funding
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI Xiaokui Mo · 2013 to 2026
$26.0MUnderstanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca · 2020 to 2026
$19.5MOncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune MicroenvironmentR01NS110942 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca, Hiroshi Nakashima · 2019 to 2026
$3.4MNext Gen Virotherapy for GBMR01NS127473 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Balveen Kaur · 2022 to 2026
$2.6MHarnessing Artificial MicroRNA Clusters Against Glioblastoma Epigenetic Plasticity and Resistance to TherapyR01NS116144 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI PERUZZI, PIER PAOLO · 2020 to 2025
$2.1MOncolytic virotherapy and immunotherapy in the treatment of brain tumorsF32CA186542 · NCI · OHIO STATE UNIVERSITY · PI JAIME-RAMIREZ, ALENA CRISTINA · 2015 to 2016
$113kNCI NIH HHS F32 CA186542NCI NIH HHS P01 CA163205NCI NIH HHS P01 CA236749NINDS NIH HHS R01 NS110942NINDS NIH HHS R01 NS116144NINDS NIH HHS R01 NS127473
Abstract
Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM)
Indexed as
Brain NeoplasmsGlioblastomaHerpesvirus 1, HumanOncolytic VirotherapyOncolytic VirusesHumansNestinReproducibility of ResultsSurvival AnalysisT-LymphocytesTreatment OutcomeTumor MicroenvironmentViral Proteinsgamma 34.5 protein, Human herpesvirus 1NestinViral Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06551909ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.